Vimarsana
Biggest News Aggregation in the World

Page 13 - Weiler Engineering Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Weiler Engineering Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Weiler Engineering Inc Today - Breaking & Trending Today

08.19.21 -- Bioprocessing Partners Poised To Meet Your Demand - Vimarsana News

08.19.21 -- Bioprocessing Partners Poised To Meet Your Demand

08/19/21 Pharmaceutical Online Newsletter

05.28.21 -- Pharma Process Equipment Partners Prepared To Help In 2021 - Vimarsana News

05.28.21 -- Pharma Process Equipment Partners Prepared To Help In 2021

05/28/21 Pharmaceutical Online Newsletter

05.27.21 -- Small Molecule Drug Substance Outsourcing - Vimarsana News

05.27.21 -- Small Molecule Drug Substance Outsourcing

05/27/21 Pharmaceutical Online Newsletter

04.20.21 -- FDA Inspections: Are Changes On The Horizon? - Vimarsana News

04.20.21 -- FDA Inspections: Are Changes On The Horizon?

04.20.21 -- FDA Inspections: Are Changes On The Horizon?     To get the most out of data, you must ensure they are findable, accessible, interoperable, and reusable — F.A.I.R. for short. Organizations simply don’t have the infrastructure in place to be able to capture data with context and then store them so that they can be searched and accessed with ease. We’ll explore how you can change that using the F.A.I.R. principles, which have been recognized as standards to enable for that potential to be realized. Featured Editorial By Kalah Auchincloss, Gr...

03.09.21 -- Incorporating Excipients Into QbD Studies For Drug Development -- An Introduction - Vimarsana News

03.09.21 -- Incorporating Excipients Into QbD Studies For Drug Development -- An Introduction

03.09.21 -- Incorporating Excipients Into QbD Studies For Drug Development -- An Introduction     Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs.   Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more!     By Brian Carlin (DFE Pharma), Chris Moreton (FinnBrit Consulting), Dave Schoneker (Black Diamond Consulting), K...